See more : Artec Global Media, Inc. (ACTL) Income Statement Analysis – Financial Results
Complete financial analysis of Poolbeg Pharma PLC (POLBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Poolbeg Pharma PLC, a leading company in the Biotechnology industry within the Healthcare sector.
- Cohen & Steers, Inc. (CNS) Income Statement Analysis – Financial Results
- Century Financial Corporation (CYFL) Income Statement Analysis – Financial Results
- Siasun Robot&Automation Co.,Ltd. (300024.SZ) Income Statement Analysis – Financial Results
- VIB Vermögen AG (VIBBF) Income Statement Analysis – Financial Results
- Mace Security International, Inc. (MACE) Income Statement Analysis – Financial Results
Poolbeg Pharma PLC (POLBF)
About Poolbeg Pharma PLC
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 26.00K | 26.00K | 18.00K |
| Gross Profit | -26.00K | -26.00K | -18.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.68M | 2.20M | 414.00K |
| General & Administrative | 3.38M | 3.06M | 2.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 3.38M | 3.06M | 2.03M |
| Other Expenses | -26.00K | 0.00 | 0.00 |
| Operating Expenses | 5.04M | 4.99M | 2.34M |
| Cost & Expenses | 5.04M | 4.99M | 2.34M |
| Interest Income | 0.00 | 209.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 26.00K | 26.00K | 18.00K |
| EBITDA | -4.66M | -4.96M | -3.09M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.69M | -4.99M | -2.34M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 181.00K | 209.00K | 0.00 |
| Income Before Tax | -4.51M | -4.78M | -2.34M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 574.00K | -91.00K | 42.00K |
| Net Income | -3.93M | -4.69M | -2.34M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -9.37 | -0.01 |
| EPS Diluted | -0.01 | -9.37 | -0.01 |
| Weighted Avg Shares Out | 497.59M | 500.00K | 317.23M |
| Weighted Avg Shares Out (Dil) | 500.00M | 500.00K | 317.23M |
Poolbeg Pharma receives initial results from human challenge clinical study
Poolbeg Pharma's new flu jab safely completes first clinical trial
Poolbeg Pharma's roadmap a ‘catalyst' for share prices
Poolbeg Pharma hails completion of AI model to identify potential flu drugs
Poolbeg Pharma to hold capital markets day this month
Poolbeg Pharma: Market starting to recognise the impact of recent progress
Poolbeg Pharma consortium wins grant to develop oral vaccines
Poolbeg Pharma and partner find first RSV drug targets using AI
Poolbeg Pharma CEO buys stock in the drug developer
Poolbeg Pharma enhances the patent protection around flu asset
Source: https://incomestatements.info
Category: Stock Reports